A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Clinical trial NCT04590326 · RECRUITING

Trial details

NCT number: NCT04590326
Sponsor: Regeneron Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Endometrial Cancer

Start date: 2020-12-08
Primary completion: 2027-03-25
Enrollment: 612

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.